Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance
- PMID: 2369939
- DOI: 10.1111/j.1600-0609.1990.tb00395.x
Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance
Abstract
In order to evaluate the clinical significance of the timing of diagnosis in chronic lymphocytic leukemia (CLL), we studied the diagnostic latency (DL), a variable related both to lymphocyte count and to lymphocyte doubling time (LDT), which points out the interval between the date of CLL diagnosis and the time at which it could have been made (lymphocyte count in peripheral blood of at least 5.0 x 10(9)/l). In two different series accounting for 221 previously untreated CLL patients the trends of the DL tended to decrease as the risk increased. In other words, the more advanced the clinical stage the shorter the DL. On the other hand, the values of lymphocyte accumulation rate (LAR), which defines the speed at which the number of lymphocytes increases over the time, were significantly lower in earlier stages of disease. Both DL and LAR had a significant impact on survival when investigated by means of univariate analysis. In a Cox's regression analysis applied to a training set of 122 patients, the combination of international clinical stages, LAR and age had the strongest value in predicting survival. The resulting model was validated in an independent subset of 99 patients (test-set cases) leading to a classification of patients into low-, intermediate-, and high-risk groups with 5-year survival rates of 89%, 31% and 8%, respectively, and with distinctively different annual mortality rates (p less than 0.001). Finally, when multivariate analysis was applied to study disease progression, LAR was the first variable to enter the regression model (p = 0.0001).
Similar articles
-
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.Haematologica. 2002 Jun;87(6):602-8. Haematologica. 2002. PMID: 12031916
-
High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.Eur J Haematol. 2009 Apr;82(4):260-6. doi: 10.1111/j.1600-0609.2008.01196.x. Epub 2009 Jan 6. Eur J Haematol. 2009. PMID: 19187271
-
Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.Cancer. 1987 Dec 1;60(11):2712-6. doi: 10.1002/1097-0142(19871201)60:11<2712::aid-cncr2820601122>3.0.co;2-1. Cancer. 1987. PMID: 3677006
-
Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.Haematologica. 1995 Mar-Apr;80(2):176-93. Haematologica. 1995. PMID: 7628755 Review.
-
A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis.Mayo Clin Proc. 1992 Apr;67(4):349-53. doi: 10.1016/s0025-6196(12)61551-1. Mayo Clin Proc. 1992. PMID: 1548950 Review.
Cited by
-
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/14651858.CD012022.pub2. Cochrane Database Syst Rev. 2020. PMID: 32735048 Free PMC article.
-
AgNOR clusters as a parameter of cell kinetics in chronic lymphocytic leukaemia.Clin Mol Pathol. 1996 Dec;49(6):M357-60. doi: 10.1136/mp.49.6.m357. Clin Mol Pathol. 1996. PMID: 16696103 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous